FDC launched India's first oral suspension of Favipiravir - Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19.
This prescription-only solution is currently available at all retail medical outlets and hospital pharmacies across the country.
The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.
India, with the second highest number of cases globally, is seeing about 50,000 cases being added every day. Though on a decline, the second wave is far from over and there are fears of an oncoming third wave.
Mayank Tikkha, General Manager - Business Development & Commercial Excellence, FDC commented, With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease.
The announcement was made after market hours yesterday, 12 July 2021. Shares of FDC rose 1.88% to settle at Rs 374.60 yesterday.
FDC is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU